|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 90 GBX | -2.70% |
|
-10.00% | -21.74% |
| 05-23 | Celadon ships to US; Oxford BioDynamics-Goodbody pact | AN |
| 05-14 | Headlam warns of loss; EnSilica predicts revenue rise | AN |
Celadon Pharmaceuticals Plc reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was GBP 0.075 million compared to GBP 0.024 million a year ago. Net loss was GBP 7.14 million compared to GBP 17.01 million a year ago.
Basic loss per share from continuing operations was GBP 0.115 compared to GBP 0.297 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -21.74% | 77.71M | |
| +38.59% | 727B | |
| -7.89% | 347B | |
| +15.66% | 319B | |
| +0.24% | 274B | |
| +12.97% | 238B | |
| +7.08% | 204B | |
| -6.50% | 203B | |
| +4.23% | 161B | |
| -1.70% | 160B |
CELADON PHARMACEUTICALS PLC 
